SOLIGENIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.414 USD | -0.24% |
|
+2.02% | -45.32% |
| 04-25 | Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa | CI |
| 04-15 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| Sales 2024 * | 800K 1.1M | Sales 2025 * | 900K 1.23M | Capitalization | 5.9M 8.07M |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -10.95M | Net income 2025 * | -9M -12.32M | EV / Sales 2024 * | 7.37 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.55 x |
| P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-0.73
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.93% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.24% | ||
| 1 week | +2.02% | ||
| Current month | -31.00% | ||
| 1 month | -31.00% | ||
| 3 months | -35.31% | ||
| 6 months | -15.84% | ||
| Current year | -45.32% |
1 week
0.38
0.44
1 month
0.370.93
Current year
0.371.20
1 year
0.374.20
3 years
0.3721.90
5 years
0.3753.10
10 years
0.37442.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 06-07-31 | |
Jonathan Guarino
DFI | Director of Finance/CFO | 51 | 19-09-10 |
Richard Straube
CTO | Chief Tech/Sci/R&D Officer | 72 | 14-01-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 06-07-31 | |
Gregg Lapointe
BRD | Director/Board Member | 65 | 09-02-28 |
Robert Rubin
BRD | Director/Board Member | 78 | 09-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.414 | -0.24% | 120,404 |
| 24-04-26 | 0.415 | -2.81% | 269,354 |
| 24-04-25 | 0.427 | +11.49% | 684,696 |
| 24-04-24 | 0.383 | -4.25% | 497,507 |
| 24-04-23 | 0.4 | -1.43% | 448,982 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm
More quotes
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.414
USD
Average target price
3.5
USD
Spread / Average Target
+745.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.32% | 5.9M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.60% | 22.18B | |
| -16.67% | 21.2B | |
| -8.49% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- SNGX Stock
